Back

Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstroms Macroglobulinemia- a single center real world retrospective analysis

Gupta, V.; Podder, D.; Saha, S.; Shah, B.; Ghosh, S.; Kumar, J.; Jacoby, A. P.; Nag, A.; Chattopadhyay, D.; Javed, R.; Rath, A.; Chakraborty, S.; Demde, R.; Vinarkar, S.; Parihar, M.; Zameer, L.; Mishra, D.; Chandy, M.; Nair, R.

2026-04-14 hematology
10.64898/2026.04.10.26350611 medRxiv
Show abstract

Waldenstrom macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of [≥] 10% lymphoid cells in BM that exhibit plasmacytoid or plasma cell differentiation that secretes an IgM monoclonal protein. This is a retrospective analysis of 89 patients of WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients of WM. The median age of the entire cophort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations were seen in 81.8% and 2.4% cases. BR was the most common regimen used (52.8%). Overall response rates were seen at 87.8%. Median overall survival, progression free survival and time to next treatment is 8.49 years, 2.15 years and 3.88 years. BR regimen was associated with highest event free survival.

Published in Indian Journal of Hematology and Blood Transfusion · not in our set (fewer than 10 published preprints to learn from) · training set

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.